参考文献
(在框内滑动手指即可浏览)
[1] 邹声泉,张林.全国胆囊癌临床流行病学调查报告 [J].中国实用外科杂志,2000,20(1):43-46.
[2] Dursun N,Escalona OT,Roa JC,et al.Mucinous carcinomas of the gallbladder: clinicopathologic analysis of 15 cases identified in 606 carcinomas[J].Arch Pathol Lab Med,2012,136(11):1347-1358.
[3] Vallonthaiel AG,Yadav R,Jain D,et al.Mucinous adenocarcinoma of gallbladder: Subcategorisation on fine-needle aspiration cytology[J].Diagn Cytopathol,2019,47(2):110-113.
[4] 刘家秒,胡志前,周海洋,等.胆囊黏液腺癌引起阻塞性黄疸3例诊治体会[J].肝胆胰外科杂志,2010,22(3):256-257.
[5] Gupta R,Indulkar S,Varshney R,et al.Mucinous adenocarcinoma of gallbladder presenting as acute calculous cholecystitis[J].Cureus,2021,13(4):e14548.
[6] Singh SK,Pujani M,Bahadur S,et al.Mucinous carcinoma of the gall bladder-An incidental diagnosis of a rare variant[J].J Cancer Res Ther,2015,11(4):1045.
[7] Yamamoto A,Ozeki Y,Ito Y,et al. A case of well differentiated mucinous carcinoma of the gallbladder[J].Nihon Shokakibyo Gakkai Zasshi,2010,107(11):1821-1827.
[8] Joo YE,Kim HS,Choi SK,et al.Case of mucinous adenocarcinoma with porcelain gallbladder[J].J Gastroenterol Hepatol,2003,18(8):995-998.
[9] 刘奔,成昱昊,葛一亨,等.胆囊黏液腺癌五例临床诊治体会[J].中华医学杂志,2021,101(42):3506-3508.
[10] Bharti S,Bharti JN,Puranik A,et al.Incidental finding of primary mucinous adenocarcinoma of gall bladder: a histopathological diagnosis[J].J Gastrointest Cancer,2021,52(1):320-324.
[11] Fukuda T,Sakimoto Y,Narita K,et al.Mucinous carcinoma of the gallbladder with signet ring cells[J].Radiol Case Rep,2017,12(4):701-705.
[12] Ishiguro S,Onaya H,Esaki M,et al.Mucin-producing carcinoma of the gallbladder: evaluation by magnetic resonance cholangiopancreatography in three cases[J].Korean J Radiol,2012,13(5):637-642.
[13] Kuroki M,Sato K,Kashimura J,et al. A case of poorly differentiated mucinous carcinoma of the gallbladder with remarkable imaging features[J].Nihon Shokakibyo Gakkai Zasshi,2003,100(10):1224-1228.
[14] Liu F,Hu HJ, Ma WJ,et al. Prognostic significance of neutrophil-lymphocyte ratio and carbohydrate antigen 19-9 in patients with gallbladder carcinoma [J]. Medicine, 2019, 98(8):e14550.
[15] Wen Z, Si A,Yang J,et al. Elevation of CA19-9 and CEA is associated with a poor prognosis in patients with resectable gallbladder carcinoma [J]. HPB,2017,19(11):951-956.
[16] Liu F,Wang JK, Ma WJ,et al. Clinical value of preoperative CA19-9 levels in evaluating resectability of gallbladder carcinoma [J]. ANZ J Surg,2019, 89(3):E76-E80.
[17] 孙学军,石景森,王林,等.原发性胆囊癌诊治分析(附1222例报告)[J].中国实用外科杂志,2014,34(2):179-182.
[18] Zou RQ,Hu HJ, Liu F,et al. Comparison of clinicopathological characteristics of mucinous adenocarcinoma and conventional adenocarcinoma of gallbladder[J/OL]. Asian J Surg, 2022,[2022-10].https:///10.1016/j.asjsur.2022.03.094.
[19] Tian H,Matsumoto S,Takaki H,et al.Mucin-producing carcinoma of the gallbladder: imaging demonstration in four cases[J].J Comput Assist Tomogr,2003,27(2):150-154.
[20] Huang CP,Chiou YY,Chou YH,et al.Imaging findings in mucin-producing carcinoma of the gallbladder[J].J Formos Med Assoc,2006,105(5):427-430.
[21] 中华医学会外科学分会胆道外科学组,中国医师协会外科医师分会胆道外科专业委员会.胆囊癌诊断和治疗指南(2019版)[J].中华外科杂志,2020,58(4):243-251.
[22] Benson AB,D'Angelica MI,Abbott DE,et al.Hepatobiliary cancers, version 2.2021,NCCN clinical practice guidelines in oncology[J].J Natl Compr Canc Netw,2021,19(5):541-565.
[23] Nagino M,Hirano S,Yoshitomi H,et al.Clinical practice guidelines for the management of biliary tract cancers 2019: The 3rd English edition[J].J Hepatobiliary Pancreat Sci,2021,28(1):26-54.
[24] 孙旭恒,任泰,耿亚军,等.中国胆囊癌外科治疗现状与病理学特征多中心回顾性研究(附4345例报告)[J].中国实用外科杂志,2021,41(1):99-106.
[25] Xiang JX,Zhang XF,Weber SM,et al.Identification of patients who may benefit the most from adjuvant chemotherapy following resection of incidental gallbladder carcinoma[J].J Surg Oncol,2021,123(4):978-985.
[26] Takada T,Amano H,Yasuda H,et al.Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma[J].Cancer,2002,95(8):1685-1695.
[27] Valle J,Wasan H,Palmer DH,et al.Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer[J].N Engl J Med,2010,362(14):1273-1281.
[28] Okusaka T,Nakachi K,Fukutomi A,et al.Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan[J].Br J Cancer,2010,103(4):469-474.
[29] 龚伟,吴向嵩,杨自逸.胆囊癌转化治疗模式探索与思考 [J].中国实用外科杂志,2022,42(2):163-166.
[30] 吕文杰,刘颖斌.胆道恶性肿瘤药物治疗进展 [J].中国实用外科杂志,2020,40(4):468-471.
[31] Ben-Josef E,Guthrie KA,El-Khoueiry AB,et al.SWOG S0809: A phase II intergroup trial of adjuvant capecitabine and gemcitabine followed by radiotherapy and concurrent capecitabine in extrahepatic cholangiocarcinoma and gallbladder carcinoma[J].J Clin Oncol,2015,33(24):2617-2622.
[32] Yokoyama T,Makino H,Hirakata A,et al.Conversion surgery for metastatic pancreatic mucinous carcinoma responsive to systemic chemotherapy with modified FOLFIRINOX: A case report[J].J Nippon Med Sch,2019,86(5):284-290.